Photofrin Available for Esophageal Palliation
WASHINGTON--The FDA has approved QLT PhotoTherapeutics' light-activated drug Photofrin (porfimer sodium) for the palliative treatment of esophageal constriction in patients with advanced esophageal cancer.
WASHINGTON--The FDA has approved QLT PhotoTherapeutics' light-activateddrug Photofrin (porfimer sodium) for the palliative treatmentof esophageal constriction in patients with advanced esophagealcancer.
Photofrin is given intravenously, then activated by nonthermallight from a medical laser delivered via fiberoptic cables intothe esophagus. Once activated, the agent produces free radicalsthat help destroy cancer cells.
Studies showed that the treatment gave patients a higher qualityof life by allowing them to swallow again on their own.
QLT (Vancouver, BC) has entered into an agreement with New YorkCity-based Sanofi Winthrop to market Photofrin, the first formof photodynamic therapy (PDT) to receive FDA approval.
Two Laser Systems
The FDA also granted marketing clearance to two laser systemsfor use with Photofrin: Coherent, Inc.'s Lambda Plus PDL.1 andPDL.2, and Laserscope's KTP/532 and KTP/YAG. A PDT Dye Moduleallows the Laserscope machines to be adapted for use in PDT.
Tiragolumab Combo Improves PFS/OS Vs Chemo in Esophageal Cancer
January 20th 2024Data from the phase 3 SKYSCRAPER-08 trial may support tiragolumab plus atezolizumab and chemotherapy as an alternative frontline treatment option for those with locally advanced or metastatic esophageal squamous cell carcinoma.
Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology
September 20th 2022Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.
Lenvatinib Combo Demonstrates Safety, Activity in Metastatic ESCC
October 23rd 2023Investigators will continue to assess the efficacy and safety of lenvatinib plus pembrolizumab and chemotherapy as frontline treatment for patients with metastatic esophageal squamous cell carcinoma in part 2 of the LEAP-014 study.
